Search clinical trials for: COPEGUS (ribavirin)

Total 1008 results

AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy

Chronic Hepatitis C | Hepatitis C Virus | HCV | Direct-Acting Antiviral Agent (DAA)-Experienced
ANRS, Emerging Infectious Diseases
Institut Pasteur

Withdrawn

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C (ViZIR)

Chronic Hepatitis C

Egypt
Brooke Army Medical Center
T.R.U.E. Research Foundation

Completed

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)

Hepatitis C Infection
Idera Pharmaceuticals, Inc.

Completed

Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients

Hepatitis C, Treatment Naïve, Genotype 1 Patients

France
Gilead Sciences

Completed

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Hepatocellular Carcinoma | Hepatitis C

United States, New Zealand, Spain
Bristol-Myers Squibb

Completed

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin (D-LITE)

Hepatitis C

United States
Anna Cruceta

Completed

HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (BOC-HIV)

HIV Infections | Hepatitis C | COINFECTION

Spain
University of Catania

Completed

Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability

Depression | Work Ability

Italy
Foundation for Liver Research

Completed

Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders (SCIN-C)

Chronic Hepatitis C

Netherlands
AbbVie

Completed

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
Icahn School of Medicine at Mount Sinai
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Hoffmann-La Roche

Completed

Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers

Hepatitis C

United States
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
The University of Texas Health Science Center,...
Astellas Pharma US, Inc.

Withdrawn

Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment

Hepatitis C

United States
AbbVie

Completed

A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) (AGATE-1)

Hepatitis C Virus
Merck Sharp & Dohme LLC

Completed

Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)

Hepatitis C, Chronic
Center For Hepatitis C, Atlanta, GA

Completed

The SIM-SOF Trial for Hepatitis C

Chronic Hepatitis C

United States
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (NEXT-1)

Hepatitis C, Chronic
Cellectar Biosciences, Inc.

Completed

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy (NOV-205)

Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Terminated

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype (CONCISE)

Hepatitis C, Chronic

United States, Austria, Canada, Germany, Israel, Poland
Bristol-Myers Squibb

Withdrawn

Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients (COMMAND-Asia)

Hepatitis C
Debiopharm International SA

Completed

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

Hepatitis C

Romania, Italy, Hungary, Taiwan, Turkey, Belgium, Spain, Germany, Australia, France, United States, United Kingdom, Poland, Puerto Rico
Research Institute of Child Nutrition, Dortmund

Completed

Modification in Complementary Food Composition to Improve the Status of Iron and Fatty Acids in Infants. (DINO)

Iron Status | Fatty Acid Status

Germany
Conatus Pharmaceuticals Inc.

Terminated

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Hepatitis C

United States
AbbVie
IST GmbH, Germany

Completed

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C

Chronic Hepatitis C
French National Agency for Research on AIDS and...

Terminated

Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance (PEGLIST C)

Insulin Resistance | Chronic Hepatitis C

France
Merck Sharp & Dohme LLC

Completed

Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) (POMOSCH)

Hepatitis C, Chronic
National Institute of Allergy and Infectious Diseases...

Completed

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

HIV Infections | Hepatitis C

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

Chronic Hepatitis C | Hepatitis C Virus
Weill Medical College of Cornell University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

Hepatitis C

United States
AbbVie
IST GmbH, Germany

Completed

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Chronic Hepatitis C, Genotype 1 or 4
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

Hepatitis C Virus Infection

United States, Italy, United Kingdom, Germany, Belgium, Russian Federation, New Zealand, Australia
AbbVie

Completed

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

Chronic Hepatitis C
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection

Hepatitis C

United States, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation

Hepatitis C | Cirrhosis | Portal Hypertension | With or Without Liver Decompensation

United States, Spain, New Zealand, Australia, France
Gilead Sciences

Completed

Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection

Hepatitis C

Spain, Netherlands, Austria, France, United Kingdom, Italy, Estonia, Germany, Poland, Sweden
Gilead Sciences
Quintiles, Inc.

Completed

Safety Study of Regimens of Sofosbuvir, GS-0938, and Ribavirin in Patients With Chronic Hepatitis C Infection (QUANTUM)

Hepatitis C, Chronic

United States, Puerto Rico
AbbVie

Completed

Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults

Chronic Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
Hoffmann-La Roche

Completed

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

France, United States, Canada, Germany, Spain, Italy, Puerto Rico
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients

Chronic Hepatitis C

Japan
Merck Sharp & Dohme LLC

Completed

Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1)

Hepatitis C | Hepatitis C, Chronic
Gilead Sciences
Merck Sharp & Dohme LLC

Completed

Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection

Hepatitis C

Japan
Merck Sharp & Dohme LLC

Completed

5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

Hepatitis C, Chronic
Bausch Health Americas, Inc.

Completed

Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19

COVID19

Greece, Mexico
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

Hepatitis C
Sheikh Zayed Medical College

Completed

Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

Hepatitis C | Hepatitis C Relapse

Pakistan
Merck Sharp & Dohme LLC

Completed

Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793)

Hepatitis C
Merck Sharp & Dohme LLC

Terminated

Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

Hepatitis C, Chronic | Insulin Resistance
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C

3

Subscribe